Obesity 1
Obesity 1
Obesity 1
net/publication/375061401
CITATIONS READS
0 32
3 authors, including:
All content following this page was uploaded by Merin Iype Chandanathil on 29 October 2023.
According to 2019 statistics provided by OurWorldData, cardiovascular diseases are the leading cause of
death worldwide [4]. High-risk factors for cardiovascular diseases include high blood pressure, diabetes, high
cholesterol, physical inactivity, and an unhealthy diet [5]. Notably, there is a very high correlation between
the above-mentioned risk factors and obesity [6]. As the connection between obesity and cardiovascular
disease continues to be supported by medical evidence, it stands to reason that understanding the causes of
obesity should be a high priority for the global healthcare community. Commonly reported causes of obesity
include long-term imbalance between energy intake versus energy expenditure, excessive alcohol intake,
limited physical activity, and medical conditions such as hypothyroidism, polycystic ovarian syndrome, and
Cushing’s syndrome. Other risk factors for obesity that have gained increasing traction include poor sleep
quality, poor stress management and emotional instability [7]. Less commonly discussed are the genetic
factors that contribute to obesity and the interplay between those factors and the external environment,
which is the main focus of epigenetics.
Epigenetic research studies how environmental and lifestyle factors such as climate, diet, water intake, etc.
affect the expression of a person's genes and production of their structural and functional proteins. An
important difference to note between epigenetic changes to DNA and genetic mutations is that epigenetic
changes are reversible and do not affect the base genetic sequence. Although the core DNA remains
fundamentally unchanged, epigenetic modifications can positively or negatively influence the way the cell
machinery reads DNA; thereby, speeding, slowing or even stopping the production of proteins that are
essential for daily functions and energy metabolism [8]. Our current knowledge of epigenetic processes
Review
DNA methylation
DNA methylation is a type of post-translational modification mediated by a family of enzymes known as
DNA methyltransferases (DNMTs). During this process, methyl groups are added, through covalent bonding,
to cytosine residues in areas of DNA where cytosine residues are followed by guanine residues (CpG sites) [9].
The result of DNA methylation is gene silencing. This is facilitated by the attachment of binding proteins to
methylation sites and, subsequently, the association of the binding proteins with histone deacetylases. This
interaction leads to chromatin remodeling and, ultimately, decreases access to transcription binding sites
[10]. In nature, well-regulated DNA methylation is responsible for normal genetic processes such as the
production of Barr bodies (inactivated X chromosomes), selective silencing of imprinted genes, cell
differentiation and, by extension, tissue differentiation [11].
Strong associations between aberrant DNA methylation and various disorders such as neuropathies,
malignancies, and metabolic dysfunctions such as obesity are reported [12]. Chief among the genes
associated with the development of obesity are the leptin and adiponectin genes. Leptin is a protein
hormone synthesized and secreted from adipose tissue that helps regulate body weight by reducing appetite
[12]. To accomplish this, leptin stimulates leptin receptors on pro-opiomelanocortin (POMC) neurons in the
hypothalamus [13] which then releases melanocyte-stimulating hormone (MSH) [14]. MSH acts on
hypothalamic neurons expressing melanocortin-4 receptor (MC4R) thereby suppressing appetite via
downstream signaling [15]. While many studies avoid linking the methylation status of the leptin gene to
obesity in a cause-and-effect context, it is worth noting that a correlation has been made between the
observation of hypomethylation of the leptin gene and the obesity phenotype [16-18]. As gene
hypomethylation is typically linked to increased gene activity (decreased gene silencing), the relationship
between leptin gene hypomethylation and obesity may reflect the leptin resistance observed in obese
populations as dysregulated exposure to a stimulus can result in a decreased sensitivity of receptors to that
stimulus [13]. In other words, being obese may cause increased leptin release as the body attempts to correct
the excessive energy intake by upregulating appetite suppression to control tendencies to overindulge.
When excessive consumption of energy substrates (food) persists, leptin levels may remain abnormally high
as the body continues to try to curb eating. As a result, hypothalamic neurons may become desensitized to
baseline levels of the hormone and manifest leptin resistance. Alternatively, it is possible that, through
mechanisms requiring more research, hypothalamic neurons become resistant to leptin before the
development of obesity. The resultant failure of appetite suppression could then lead to overeating and
obesity. Knowing the role of leptin in appetite regulation makes this hormone an excellent candidate for
continued research as targeting the activity of this gene may allow physicians to apply epigenetic principles
to regulate the appetites of their obese patients.
In contrast to the POMC gene, activation of the neuropeptide Y ( NPY) gene is associated with hunger and,
therefore, increased food intake. In obese individuals, hypermethylation of POMC has been observed
whereas NPY tends to be hypomethylated [17]. Since DNA methylation is most associated with gene
silencing, it stands to reason that a cause-and-effect relationship potentially exists between obesity and
excessive silencing of the satiety gene and/or insufficient silencing of the hunger gene. These findings
further support the existence of a relationship between the obesity phenotype and the methylation status of
genes that control the body’s desire for food and, therefore, food intake. POMC and NPY could, therefore, be
used as pharmaceutical targets for reversing obesity. Drugs tailored towards the methylation status
of POMC and/or NPY may be able to suppress a patient’s appetite and jumpstart weight loss simply by way of
reducing food consumption.
Aberrant methylation of other genes has also been linked to obesity, such as the beta-3 adrenoceptor
gene (ADRB3) [16] and the insulin-like growth factor-2 gene (ILGF2) [18]. ADRB3 codes for receptors bearing
the same name. In white adipose tissue, they are involved in the regulation of lipolysis while in brown
adipose tissue they are involved in the regulation of thermogenesis. Studies conducted in ADRB3-knockout
mice concluded that diminished activity of ADRB3 led to abnormal lipolysis, increased lipid storage and
obesity in the mice. In humans, ADRB3 deficiency has been associated with an increased risk of developing
cardiovascular diseases and obesity [19]. Therefore, like POMC and NPY, altering the methylation status
of ADRB3 by therapeutic agents is another excellent candidate for continued research in the efforts against
obesity. ILGF2 plays a vital role in the regulation of body structure and tissue growth. The gene product,
ILGF2, is a protein that activates insulin-like growth factor 1 (ILGF1) receptors. The activated ILGF1
receptors go on to promote anabolic processes within the body, such as skeletal muscle growth. The
methylation status of ILGF2 is reported to correlate negatively with body mass index [20]. In other words,
hypomethylation of ILGF2 and, therefore, increased activation of ILGF1 receptors is associated with a higher
BMI, which is consistent with fat storage as an anabolic process [20]. This information also places ILGF2,
along with the ILGF1 receptor on the growing list of potential therapeutic targets against obesity.
Hypoxia-inducible factor
Hypoxia-inducible factor (HIF) is a transcription factor triggered by decreased blood and/or tissue oxygen
levels. HIF regulates many different intracellular and physiological processes by regulating the expression of
a variety of genes. HIF is a protein complex composed of one of three alpha subunits (HIF1A, HIF3A or
EPAS1) and a beta subunit (ARNT). While the main function of HIF is as described above, evidence continues
to emerge in support of HIF’s role in energy balance, metabolic processes, and obesity. In genetically
modified mice exposed to a high-fat diet, interruption of adipocyte HIF1A or ARNT, specifically, has been
associated with decreased adipogenesis, prevention of obesity, and decreased instances of insulin resistance
[23]. Therefore, HIF1A and ARNT may be reasonable targets in terms of preventative interventions in
individuals with a genetic predisposition towards obesity. A connection between the methylation status of
HIF3A and BMI has been demonstrated where the amount of HIF3A gene methylation exhibited a linear
relationship to BMI [23]. It is thought that upregulation of HIF3A may be the result of the hypoxia associated
with sleep apnea or other disordered breathing secondary to high BMI and, therefore, obesity [23]. A novel
use of HIF3A may be as a biomarker for the likelihood of developing obesity or as a biomarker for diagnostic
confirmation of obesity-induced sleep apnea. Notably, whereas this line of research did not define a cause-
effect relationship between BMI and HIF3A, such a relationship may exist. In the event that increased
methylation of HIF3A is found to be a cause of increased adiposity, then HIF3A may be considered a
potential therapeutic target against the development of obesity.
Histone modification
Histones are basic globular proteins that are integral to DNA structure. For DNA to fit within cell nuclei, it
must wrap itself around histone complexes. These DNA-histone complexes, known as nucleosomes,
condense DNA into compact structures known as chromatin. Of the post-translational modifications
associated with histones, acetylation and methylation are the most widely discussed within the context of
the relationship between epigenetics and obesity. Histone acetylation results in upregulated gene
expression as the DNA structure becomes more relaxed and, therefore, DNA is more accessible for
transcription. In contrast, histone methylation may upregulate or downregulate gene expression by
disrupting or enhancing the DNA-histone interaction [17]. Interestingly, it is the location and the extent of
the histone methylation that determines the result of this post-translational modification. Enzyme families
responsible for histone modifications include histone-specific acetyltransferases, deacetylases,
methyltransferases and demethylases [17].
In one example of histone modification, liver cells extracted from animals fed a high-fat diet exhibited an
increase in histone acetylation at the location of histone 3 lysine 9 (H3K9) and histone 3 lysine 18 (H3K18) in
relation to the tumor necrosis factor (TNF) gene [17]. In other words, a high-fat diet has been associated with
increased expression of TNF. One of the TNF proteins, more specifically TNF-a, is a cytokine produced by
several different cell types such as macrophages and adipocytes. Studies have determined that increased TNF
expression can be linked to obesity by its tendency to function as a mediator of insulin resistance [24].
Insulin resistance is a state in which the cells of the body do not exhibit their usual sensitivity to insulin
and, as a result, do not uptake glucose from the blood as efficiently as they would otherwise. This leads to
hyperinsulinemia (excessive insulin secretion) and can exacerbate or precipitate hyperglycemia [25].
Evidence supports the concept that, even in the presence of insulin resistance, adipocytes tend to maintain
their sensitivity to insulin, unlike muscle and liver cells. As muscle and liver cells fail to absorb glucose from
the blood, blood glucose levels remain abnormally high and insulin levels may rise in an attempt to correct
the hyperglycemia. Adipocytes respond to the increased hormonal stimulation by increasing their glucose
uptake and by the formation of new adipocytes to accommodate the excess energy available for storage [26].
In this way, histone acetylation with respect to TNF and the resultant insulin resistance may encourage the
emergence of the obesity phenotype. Interestingly, caloric restriction is reported to revert the increase in
acetylation to the normal type [17]. This finding lends further support to the notion that the modification
of TNF is epigenetically regulated. It has also been hypothesized that insulin may function as a negative
feedback hormone within the central nervous system (CNS) with respect to food intake [27]. It is thought
that CNS insulin resistance may disrupt this feedback inhibition loop and result in an excess of food intake
(total calories) and excessive fat storage. With this knowledge, healthcare workers may consider increasing
community education on the association between a chronic high-fat diet, insulin resistance, and obesity
especially as it pertains to diabetic patients. As the research suggests, focusing too heavily on controlling
only carbohydrate intake would be to provide incomplete information to patients on how to truly avoid
Like DNA methylation, histone modifications have also been associated with regulation of POMC and NPY.
Decreased acetylation at the location of H3K9 in relation to POMC has been associated with obesity
secondary to a high-fat diet [17]. As discussed previously, POMC is normally involved in appetite
suppression through downstream signaling. Decreased acetylation of POMC could, therefore, lead to
decreased expression of POMC, decreased appetite suppression and, subsequently, increased food intake.
Enhanced acetylation at the H3K9 locus, correlated with NPY expression, underscores the importance of
epigenetic mechanisms, wherein dietary inputs, particularly from a high-fat diet, can modulate gene
expression patterns, thereby contributing to the development of obesity through intricate molecular
pathways [17]. Since NPY is associated with hunger, increased acetylation of H3K9 could lead to increased
production of the NPY peptide which would, in turn, increase hunger and food intake.
The thyroid gland secretes both thyroxine (T4) and triiodothyronine (T3). Though T4 is secreted from the
thyroid in larger amounts than T3, T4 is peripherally converted into T3 as needed and it is T3 that is
functionally active. Early studies focused on the connection between food intake and thyroid hormone
assert that T3 production was drastically increased in lean participants during periods of excessive food
intake. Conversely, T3 was found to be decreased in periods of caloric deficit for lean and obese persons [28].
As thyroid hormone has been linked to energy expenditure, it follows that T3 would increase during
overfeeding to encourage increased energy expenditure as a means of compensating for the increased
energy intake [28]. The inverse of this logic is therefore applicable in the instance of caloric deficit. Further
to this, animal studies have proposed a direct link between thyroid hormone and appetite regulation. When
T3 was increased in the peripheral tissues it had a catabolic effect resulting in weight loss. On the other
hand, central increase of T3 (administration of T3 into the hypothalamus) resulted in anabolic effects such
as increased appetite leading to increased food intake and weight gain [28].
While knowledge concerning the function and effects of thyroid hormone appears to be vast and
continuously expanding, much less appears to be known about the function and effects of thyroid hormone
in terms of body composition from an epigenetic perspective. As previously discussed, POMC neurons
regulate appetite through the release of MSH which binds MC4R receptors on target neurons. Although
MC3R is another hypothalamic MSH receptor, MC4R has been most closely associated with regulation of
body weight. Just as thyroid stimulating hormone influences the expression of thyroid hormone, thyroid
hormone receptor (TR) association with thyroid receptor binding elements (TRE) has been found to
modulate expression of MC4R in mice. By interacting with TREs found within the MC4R gene promoter
region, T3-TR complexes have been observed to play a role in T3 suppression of MC4R protein expression
[29].
In studies on the regulation of MC4R expression by thyroid hormone, offspring of mice fed high-fat diets
had greater concentrations of circulating T3 [29], which is in accordance with our earlier discussion of T3.
Further, BMI is shown to be correlated with decreased MC4R expression, increased T3 levels, and increased
association of T3-TRb complexes with TREs at histone 3 lysine 27 (H3K27) in the MC4R promoter region.
Histone acetylation is thought to cause exposure of the promoter region of MCR4, thereby permitting
repressor molecules to bind to this site and decrease MC4R expression in the offspring of high-fat diet fed
mice [29]. In this way, TRb acts as a transcription factor that regulates the expression of MC4R. Moreover,
when T3 and T4 concentrations were pharmacologically lowered via administration of methimazole, a
thyroid hormone biosynthesis inhibitor, body weight in high-fat diet exposed pups was reduced.
Additionally, methimazole was found to prevent the downregulation of MC4R, the upregulation of T3-
TRb complexing, and therefore, the acetylation of H3K27 [29]. These results demonstrate a potential
epigenetic pathway to obesity which could be dependent on thyroid hormone. In the first instance,
decreased expression of MC4R would lead to decreased MSH activity and, therefore, decreased satiety and
increased likelihood of overeating. In the second instance, increased histone acetylation secondary to T3-
TRb interactions with TREs would also decrease MC4R expression, thereby also decreasing MSH activity [29].
The administration of methimazole adds further support to the notion that thyroid hormone may be central
to this mechanism by virtue of the finding that the drug created the opposite effects of T3. These findings
suggest several potential therapeutic targets against obesity, mostly notably T3, H3K27 and MC4R, as
manipulation of these molecules can be used to increase satiety, decrease food intake and prevent or reverse
obesity.
Lipid metabolism is essential for supporting the normal functioning of many biological processes because
lipid metabolism generates essential energy metabolites. Aberrant lipid function, therefore, can not only
lead to fat deposition but also a disruption of other metabolic processes. Long non-coding RNAs can
influence lipid metabolism through their interactions with RNA, DNA and protein molecules [30]. Such
lncRNAs may affect lipid metabolism by interacting with transcription factors and, as a result, altering their
interaction with their target genes. In this manner, two lncRNAs, AK133540 and AK142386, have been
proposed to be associated with the regulation of homeobox A3 (HOXA3) and acyl-CoA dehydrogenase 10
(ACAD10), respectively. While further research is necessary to elucidate the extent and mechanism of action
of these long noncoding RNAs on HOXA3 and ACAD10, it is important to note that products of these two
genes have been implicated in adipogenesis and energy metabolism. Although the precise mechanisms
require further investigation, AK133540 and AK142386 could potentially modulate the expression of key
genes, thereby influencing the differentiation of preadipocytes into adipocytes and/or the regulation of
obesity-related metabolic pathways [31]. Given their implicated roles in lipogenesis, the lncRNAs AK133540
and AK142386 may emerge as promising targets in gene therapy for obesity, wherein modulating their
expression or function could potentially alter adipogenic pathways and lipid storage. This would be a novel
approach to manage and possibly mitigate the metabolic and morphological alterations associated with
obesity.
In cholesterol metabolism, lncRNAs and miRNAs have been found to exhibit cross-talk that affects
cholesterol homeostasis. For example, it has been determined that microRNA 140 (miR-140) increases the
expression of a lncRNA known as NEAT1 [30]. miR-140’s upregulation of NEAT1 is reported to be critical for
adipogenesis [32]. This information may prove to be clinically relevant as increased levels of NEAT1 or miR-
140 may prove to be useful biomarkers for the detection of aberrant adipogenesis. Additionally, disruption of
the signaling pathway between NEAT1 and miR-140 may provide yet another therapeutic avenue in relation
to obesity. In view of the fundamental role of glucose in metabolic processes, dysfunctional glucose
metabolism may lead to the development of obesity. The lncRNA betalinc1 (beta long intergenic noncoding
RNA1) regulates transcription factors associated with pancreatic islet cells and, as a result, influence the
differentiation of islet cells and insulin production [30]. Epigenetic modification of lncRNA betalinc1 may,
therefore, make a person susceptible to either hypo- or hyper-insulinemia, hyperglycemia, and insulin
resistance which can lead to obesity. A novel correlation between obesity and dysfunctional glucose
homeostasis is reported to result from the downregulation of a long non-coding RNA 1810019D21Rik given
the name RIOT (regulator of insulin transcription), a lncRNA found in pancreatic beta cells [33]. RIOT
downregulation appears to inhibit DNA methyltransferase 3a degradation leading to increased methylation
of the promoter region of Nkx6.1 [33]. Nkx6.1 is a transcription factor involved in the differentiation,
development, and function of pancreatic beta cells [34]. Decreased insulin transcription and dysfunctional
glucose regulation seems to be the consequence of increased methylation of the Nkx6.1 promoter [33]. Based
on the foregoing, lncRNA RIOT and transcription factor Nkx6.1 can both be considered candidates for the
management and/or reversal of obesity-induced diabetes.
Dietary factors
There are decades worth of research and discussion available on the implications of diet on physical and
emotional health. It is common knowledge that a diet consisting of excessive calories, usually consistent
with low fruit and vegetable content, is an almost certain antecedent to obesity. Less commonly known are
the epigenetic modifications that follow obesity, which can lead to or increase the risk of other disorders and
diseases. For example, consumption of a high-fat diet for five days is shown to increase DNA methylation of
the transcription factor PPAR-gamma [17]. PPAR-gamma plays an essential role in optimal adipocyte
performance, and decreased PPAR-gamma function has been associated with lipodystrophy, insulin
resistance, and obesity [35]. Long-term exposure to a high-fat diet is also reported to upregulate histone
deacetylase 9, leading to the disruption of adipocyte differentiation which may affect adipocytes by
decreasing adiponectin synthesis [17]. Adipocyte adiponectin has several functions including support of
insulin signaling, increased insulin sensitivity, and decreasing triglyceride levels in muscle tissue [36]. There
is evidence in support of adiponectin having strong anti-atherosclerotic effects by inhibiting adhesion
molecule expression, nuclear factor kappaB activation and macrophage scavenger receptor A-1 expression
[36]. These findings suggest that epigenetic influences on both adiponectin and PPAR-gamma may
predispose an individual to dysregulation of lipid metabolism, insulin resistance and obesity.
Studies on the effects of diet on the development of cervical intraepithelial neoplasia (CIN) demonstrate
Just as substances of abuse cause a neuroadaptive response in the reward center of the brain, so too can
enticing foods. The connection between the consumption of appetizing foods and the resultant pleasure
experienced is known to be mediated by a sudden spike in dopamine (DA) levels within the mesolimbic
system. The amount of dopamine released is highly correlated to the amount of gratification experienced.
Impaired dopamine regulation can, therefore, lead to overeating even in the face of deleterious
consequences - behaviors commonly observed in individuals with the obesity phenotype. Studies have
shown the promoter region of dopamine transporter SLC6A3 to be hypermethylated after exposure to high-
fat, high-carbohydrate diets. SLC6A3, a presynaptic membrane protein, is responsible for rapid reuptake of
dopamine into presynaptic neurons, thereby limiting the action of DA [38]. Theoretically, methylation of the
SLC6A3 gene, and therefore a decrease in the SLC6A3 membrane protein, is expected to prolong the activity
of DA in the synapse. This might increase the pleasure and reward derived from the behavior of consuming a
high-fat, high-sugar diet and positively reinforce the behavior. Unsurprisingly, such behaviors may
encourage weight gain and lead to obesity.
Maternal factors
Evidence is emerging which supports the concept that the intrauterine environment exerts a significant
influence on fetal development. The period of plasticity early on in the gestational period could prove
beneficial for the developing offspring, as changes in the gestational environment that reflect the external
environment would allow for preemptive adaptation to external stimuli. However, this susceptibility to
adaptation may also be deleterious. The Developmental Origins of Health and Disease (DOHAD) hypothesis
suggests that being exposed to a harmful environment while in the womb or during the early stages of life
can have negative effects on one's health well into adulthood [18]. Subjugation to maternal obesity, famine
during gestation, nutritional supplements, drugs, alcohol, or other chemical agents can trigger epigenetic
alterations that impact the development of the embryo and placenta. Further, these epigenetic changes may
alter biological processes that regulate adiposity. Based on current knowledge, the two main targets for
epigenetic changes that influence fetal predisposition to obesity are regulating factors of adipocytes and
regulating factors of food intake [39].
Like dopamine, endogenous opioids also participate in the sensations of gratification and pleasure generated
in the mesolimbic system. While much is left to be discovered about the connection between the maternal
environment and modified expression of neurotransmitters in offspring, emerging research lends support
that epigenetic alterations may adversely affect endogenous opioid expression in offspring of mothers
exposed to a high-fat diet. Studies suggest that maternal ingestion of appetizing foods during the gestational
period, namely those foods high in fat, salt, and sugar, may promote a preference for such foods in the
offspring [40]. It has been hypothesized that maternal exposure to high-fat foods may alter the expression of
endogenous opioids in the mesolimbic system of offspring. This is evidenced by opioid receptor and pre-
proenkephalin (PENK) expression changes in the offspring of high-fat fed mothers. Notably, the promoter
region of PENK displays hypomethylation in offspring subjected to such maternal conditions. In accordance
with our earlier discussion surrounding DNA methylation, hypomethylation of the PENK promoter
corresponds with increased proenkephalin [40]. As research suggests that opioid receptor stimulants tend to
increase the appetite and increase food intake [40], increased PENK in offspring could easily encourage
overeating. Coupled with a preference for highly palatable foods, it is clear that maternal influences may
support the development of obesity in offspring - a condition that may easily persist into adulthood.
Fetal nutrition is shown to exert influence over the activation of adipogenesis and lipogenesis. Excessive
maternal nutrition may lead to a dramatic increase in PPAR-gamma, a transcription factor affecting the
development of subcutaneous fat. PPAR-gamma activation has been positively and directly correlated with
fetal blood glucose concentration [41]. Consequently, PPAR-gamma increased the expression of fetal
lipoprotein lipase (LPL) and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) which, in turn, promote
incorporation of free fatty acids and glucose into adipocytes [41]. In a separate study, maternal nutrition was
found to play a role in the generation of signaling molecules that affect NPY and POMC [39]. Similarly,
offspring of pregnant mice exposed to a high-fat diet for four weeks showed increased methylation of the
insulin receptor substrate 2 gene, which negatively impacts the normal functioning of insulin downstream.
Additionally, hypomethylation of the mitogen-activated protein kinase 4 (MAPK4) gene was found [39].
These changes in methylation patterns were positively correlated with increased body weight,
hyperglycemia, and insulin resistance in offspring [17]. Offspring of mothers fed a high-fat diet were found
to have hyperinsulinemia, hyperglycemia, and increased LPL and leptin gene expressions [39]. Further
support for an important influence of maternal diet on offspring phenotype comes in the form of babies
born to women with gestational diabetes mellitus. Infants born to diabetic mothers are reported to possess
significantly more adipose tissue and larger skinfold measurements compared to those exposed to
undernutrition during the gestational period [39].
The importance of maternal health during the gestational period has always been emphasized for the well-
Physical activity
Physical activity has also been linked to epigenetic changes which support the development of obesity.
Excessive and prolonged inactivity have been reported to decrease insulin sensitivity as well as promote
dysfunctional energy metabolism and mitochondrial function. Decreased DNA methylation in the regulatory
region of the PPAR-gamma coactivator 1-apha (PGC1α) gene is shown to be associated with upregulated
expression of the PGC1α [17]. The PGC1α protein interacts with transcription factors to increase the
transcription of PPAR-gamma [42]. As the PPAR-gamma protein is involved in lipid and glucose metabolism,
it makes sense that exercise would induce the activity of this protein and that exercising would put the body
in an energy deficit. PGC1α could, therefore, be a novel pharmaceutical target in obese patients who, based
on the above, would likely have increased methylation of this coactivator.
Skeletal muscle biopsies from obese and diabetic subjects before and after 16 weeks of aerobic or resistance
exercise are reported to show decreased DNA methylation of the nuclear respiratory factor 1 (NRF1) gene, a
transcription factor involved in the normal functioning of several metabolic genes [17]. The fatty acid
synthase (FASN) gene appears to exhibit increased methylation which may explain why circulating lipids
were reduced and metabolic function was improved. Resistance training resulted in the modification of
microRNAs involved in metabolism and methylation of the solute carrier family 2 (SLCA2) gene involved in
mitochondrial function and metabolism of fatty acids, which was found to be increased. These epigenetic
changes were associated with improved glucose utilization and decreased lipid content of the skeletal
muscles [17].
Table 1 summarizes the target genes and epigenetic modifications purported to reflect the important
environment-gene interactions leading to obesity.
Target
Epigenetic modification Functional outcomes
gene
Hypomethylated
NPY Increases hunger and food intake
Increased acetylation of H3K9 related to NPY
HOXA3
Two lncRNAs, AK133540 and AK142386 modulate the interactions of transcription
and Lipogenesis
factors with their target genes
ACAD10
NEAT1
or miR- miR-140 upregulates the expression of NEAT1 Adipogenesis
140
PGC1α interacts with transcription factors to enhance the transcription of PPAR- Dysregulates lipid and glucose
gamma metabolism
Hypermethylation of the SLC6A3 gene decreases the SLC6A3 membrane protein, Overeating even when aware of the
SLC6A3
causing prolonged dopamine activity negative consequences
PENK Hypomethylation of the PENK promoter corresponding to increased proenkephalin Causing overeating in offspring
NRF1 Decreased DNA methylation of the NRF1 gene, a transcription factor Affects various metabolic genes
There appear to be several pathways for epigenetic programming of the adult body weight set point.
Alterations in the fatty acid composition of breast milk, differences in the metabolic and hormonal profiles
and changes in the gut microbiota of neonatal animals and humans may all play roles in epigenetic
programming of the set point [49]. Breast milk lipids, especially fatty acids, are vital for infant development,
meeting about half of their energy needs. The polyunsaturated fatty acids (PUFAs) in breast milk can, no
doubt, impact an infant's fat deposition and growth. Over the past 30 years, there's been an increased
omega-6/omega-3 PUFA ratio in human breast milk, correlating with heightened maternal consumption of
Recent findings highlight the role of human milk oligosaccharides (HMOs) in reducing infant adiposity,
suggesting their potential in protecting against obesity when breastfeeding. Unlike infant formulas, HMOs
are abundant in human milk and may function as prebiotics, potentially aiding in reducing fat build-up by
fostering healthy gut microbiota and their resultant metabolites like short-chain fatty acids (SCFAs). SCFAs
like butyric and formic acid in breast milk, are reported to inversely correlate with infant BMI [57]. The
possible epigenetic impact of early postnatal nutrition could, therefore, stem from alterations in gut
microbiota during this developmental phase. Future studies should address the intricate links between
postnatal nutrition, gut microbiota, and their potential role in epigenetic programming of the adult body
weight set point.
Postnatal programming of the adult body weight set point may also be mediated by epigenetic influences on
insulin secretion. Hyperinsulinemia in the offspring of various animals has been linked to transference of
breast milk hormones such as insulin and leptin [58]. A role for insulin signaling in the postnatal epigenetic
reprogramming of the liver is suggested by profound effects of demethylation on insulin receptor deletion
during liver maturation [59]. In that regard, a collection of insulin target genes are shown to be impacted in
postnatal programming models, thereby providing evidence of the far-reaching consequences of hormonal
alterations in neonates [60]. Gender-based metabolic programming is shown to result from interactions
between testosterone, DNMTs and ten-eleven translocation (TET) enzymes in the ventromedial nucleus
satiety center, among other brain areas [61]. This line of research may someday help explain gender-based
differences in predilections for obesity in men compared to women. These findings on gender-based
metabolic programming, involving interactions between testosterone, DNMTs, and TET enzymes within key
brain regions open up new avenues for understanding not only obesity but also related health conditions,
such as autoimmune diseases and post-maternity weight management, which exhibit gender-based
disparities. For example, autoimmune diseases, including thyroid disorders like Hashimoto's and Graves'
disease, have a higher prevalence in women compared to men. Gender-specific metabolic programming
could potentially contribute to these differences. It is, therefore, plausible that the same molecular
interactions mentioned in the study might influence the immune system's response, making women more
susceptible to autoimmune diseases, including those affecting the thyroid gland. Another gender-specific
aspect of metabolism relates to the post-maternity period. Women often face unique challenges in
managing their weight after pregnancy. Hormonal changes, including fluctuations in estrogen and
progesterone, could interact with the brain's metabolic programming mechanisms. This research may
provide insights into why women tend to experience different post-pregnancy weight trajectories compared
to men. Such knowledge could lead to more targeted interventions and therapies, ultimately improving the
health outcomes of individuals, particularly women, who are disproportionately affected by these
conditions. Additionally, a role for high blood glucose levels interacting with TET enzymes involved in DNA
demethylation and O-GlcNAc transferase (OGT) involved in important post-translational modifications of
proteins, makes a compelling argument for a direct influence of metabolic stimuli such as hyperinsulinemia
and/or hyperglycemia on epigenetic modifications which could influence the adult body weight set point
[62].
Table 2 summarizes the epigenetic modification that can influence the body weight set point and lead to
obesity.
Adult factors
Appetite DNA methylation of the promoter region of POMC which encodes an appetite suppressor gene alpha-MSH
Adipocytes Non-coding RNAs, MiR-143 promotes adipocyte differentiation and impacts adipogenesis
High-fat diet PPARα can initiate DNA methylation in the Fgf21 gene and increase obesity caused by high-fat diets
Dysfunction of Bmal1, a crucial circadian rhythm regulator, was linked to downregulation of the neutral amino acid
Circadian rhythm
transporter SLC1A5 and reductions in uptake of the amino acids glutamine and methionine in adipocytes
Metabolic programming due to the interaction between testosterone, DNMTs, and TET enzymes in the ventromedial
Gender
satiety center
Hyperglycemia
High blood glucose levels interacting with TET enzymes involved in DNA demethylation and OGT affecting post-
and
translational modifications of proteins may directly influence the adult body weight set point
hyperinsulinemia
Neonatal factors
Neonatal Changes in the fatty acid composition of breast milk and changes in gut microbiota can cause epigenetic
influences programming of set point
Increased omega-6/omega-3 PUFA ratio in breast milk due to increased consumption of refined vegetable oils
Breast milk
causes DNA methylation in genes of white adipose tissue
Infant formula Does not contain human milk oligosaccharides and short-chain fatty acids like butyric acid and formic acid
Hormonal Transfer of hormones like insulin and leptin through breast milk can cause postnatal epigenetic reprogramming of the
alteration liver, demethylation on insulin receptor deletion during liver maturation
TABLE 2: Summary of epigenetic factors that influence body weight set point.
POMC=pro-opiomelanocortin; MSH=melanocyte stimulating hormone; MiR-143=micro RNA-143; PPARα=peroxisome proliferator-activated receptor
alpha; SLC1A5=solute carrier family 1 member 5; DNMTs=DNA methyltransferases; TET=ten-eleven translocation; OGT=O-GlcNAc transferase;
PUFA=polyunsaturated fatty acids
Summary
Figure 1 depicts the relationships between seven epigenetic mechanisms shown, in this review, to be
involved in the development of obesity.
DNA methylation, histone modifications, and the influence of the prenatal environment are some of the
mechanisms by which epigenetic changes occur. Regulated DNA methylation is necessary for a number of
biological processes, such as cell differentiation. Conversely, dysregulated DNA methylation has been
implicated in the pathogenesis of obesity because it may lead to leptin resistance through hypomethylation
of POMC. Aberrant methylation of NPY, ADRB3, IGF1, and HIF3a have all been linked to obesity. Decreased
histone acetylation of POMC and increased acetylation of NPY have been linked to obesity following
exposure to a high-fat diet. Epigenetic evidence of intergenerational effects include hypomethylation
of POMC, changes in expression of melanocortin and insulin receptors, as well as altered gene expression of
appetite-regulating dopamine and opioid-related genes in the offspring of obese mothers or those exposed
to a high-fat diet. lncRNAs are shown to be associated with disruptions in lipid, glucose and cholesterol
metabolism and several lncRNAs are more highly expressed in obese individuals compared to their normal
body weight counterparts. The most widely reported and discussed epigenetic factors involve diet and
physical activity involving hypomethylation of POMC, NPY, ADRB3, IGF, HIF3a and an activator of PPAR-
gamma.
Conclusions
Obesity has reached epidemic proportions in the developed world and its incidence continues to rise on a
yearly basis. Given that obesity is now classified as a disease, as well as a major risk factor for diabetes
mellitus, cardiovascular disease, cancer, and cerebrovascular disease, it is imperative that we attempt to
understand all facets of the pathogenesis of obesity in our quest to decrease its prevalence. The role of
epigenetics in obesity has recently come to center stage and continues to be an area where further study
would prove most beneficial in enhancing our understanding not only of how obesity occurs, but also of
potential treatments and preventive interventions. While much has been uncovered thus far, continued
investigations are necessary to establish true cause-effect relationships between epigenetic markers and the
development of obesity. Such evidence of environment-gene interaction could lead to the discovery of novel
therapeutic targets in the fight against obesity. Ongoing research to establish the cause-effect links between
epigenetic markers and obesity holds immense promise, as it could unveil the critical role of environmental
factors in influencing gene expression. This deeper understanding of environment-gene interactions may
pave the way for the identification of innovative therapeutic strategies aimed at combating obesity by
Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the
following: Payment/services info: All authors have declared that no financial support was received from
any organization for the submitted work. Financial relationships: All authors have declared that they have
no financial relationships at present or within the previous three years with any organizations that might
have an interest in the submitted work. Other relationships: All authors have declared that there are no
other relationships or activities that could appear to have influenced the submitted work.
Acknowledgements
This review performed in partial fulfillment of the Master of Health Sciences degree at the American
University of Antigua College of Graduate Studies, approval by Raymond Robinson MD, MPH, MBA,
Professor & Executive Dean.
References
1. Herrera BM, Keildson S, Lindgren CM: Genetics and epigenetics of obesity. Maturitas. 2011, 69:41-9.
10.1016/j.maturitas.2011.02.018
2. McAllister EJ, Dhurandhar NV, Keith SW, et al.: Ten putative contributors to the obesity epidemic . Crit Rev
Food Sci Nutr. 2009, 49:868-913. 10.1080/10408390903372599
3. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of
Obesity in Adults (US). Clinical guidelines for the identification, evaluation, and treatment of overweight
and obesity in adults-the evidence report. Obes Res. 1998, 6:51-209.
4. Hales CM, Carroll MD, Fryar CD, et al.: Prevalence of obesity and severe obesity among adults: United
States, 2017-2018. NCHS Data Brief. 2020, 360:1-8.
5. Slomko H, Heo HJ, Einstein FH: Minireview: epigenetics of obesity and diabetes in humans . Endocrinology.
2012, 153:1025-30. 10.1210/en.2011-1759
6. Murr R: Interplay between different epigenetic modifications and mechanisms . Adv Genet. 2010, 70:101-41.
10.1016/B978-0-12-380866-0.60005-8
7. Vo AT, Millis RM: Epigenetics and breast cancers . Obstet Gynecol Int. 2012, 2012:602720.
10.1155/2012/602720
8. Meeran SM, Ahmed A, Tollefsbol TO: Epigenetic targets of bioactive dietary components for cancer
prevention and therapy. Clin Epigenetics. 2010, 1:101-16. 10.1007/s13148-010-0011-5
9. Newman M, Blyth BJ, Hussey DJ, Jardine D, Sykes PJ, Ormsby RJ: Sensitive quantitative analysis of murine
LINE1 DNA methylation using high resolution melt analysis. Epigenetics. 2012, 7:92-105.
10.4161/epi.7.1.18815
10. Newell-Price J, Clark AJ, King P: DNA methylation and silencing of gene expression . Trends Endocrinol
Metab. 2000, 11:142-8. 10.1016/s1043-2760(00)00248-4
11. de Mello VD, Pulkkinen L, Lalli M, Kolehmainen M, Pihlajamäki J, Uusitupa M: DNA methylation in obesity
and type 2 diabetes. Ann Med. 2014, 46:103-13. 10.3109/07853890.2013.857259
12. Al-hussaniy H, Altalebi RR, Tylor FM, et al.: Leptin hormone: in brief . Med Pharm J. 2022, 1:1-3.
10.55940/medphar20221
13. Friedman JM: Leptin and the endocrine control of energy balance . Nat Metab. 2019, 1:754-64.
10.1038/s42255-019-0095-y
14. Forbes S, Bui S, Robinson BR, Hochgeschwender U, Brennan MB: Integrated control of appetite and fat
metabolism by the leptin-proopiomelanocortin pathway. Proc Natl Acad Sci U S A. 2001, 98:4233-7.
10.1073/pnas.071054298
15. Sadashiv, Modi A, Khokhar M, et al.: Leptin DNA methylation and its association with metabolic risk factors
in a northwest Indian obese population. J Obes Metab Syndr. 2021, 30:304-11. 10.7570/jomes20131
16. Samblas M, Milagro FI, Martínez A: DNA methylation markers in obesity, metabolic syndrome, and weight
loss. Epigenetics. 2019, 14:421-44. 10.1080/15592294.2019.1595297
17. Mahmoud AM: An overview of epigenetics in obesity: the role of lifestyle and therapeutic interventions . Int
J Mol Sci. 2022, 23:10.3390/ijms23031341
18. Obri A, Serra D, Herrero L, Mera P: The role of epigenetics in the development of obesity . Biochem
Pharmacol. 2020, 177:113973. 10.1016/j.bcp.2020.113973
19. Guay SP, Brisson D, Lamarche B, et al.: ADRB3 gene promoter DNA methylation in blood and visceral
adipose tissue is associated with metabolic disturbances in men. Epigenomics. 2014, 6:33-43.
10.2217/epi.13.82
20. Ács O, Péterfia B, Hollósi P, Luczay A, Török D, Szabó A: Methylation status of CYP27B1 and IGF2 correlate
to BMI SDS in children with obesity. Obes Facts. 2017, 10:353-62. 10.1159/000477462
21. Lillycrop KA, Garratt ES, Titcombe P, et al.: Differential SLC6A4 methylation: a predictive epigenetic marker
of adiposity from birth to adulthood. Int J Obes (Lond). 2019, 43:974-88. 10.1038/s41366-018-0254-3
22. Zhao J, Goldberg J, Vaccarino V: Promoter methylation of serotonin transporter gene is associated with
obesity measures: a monozygotic twin study. Int J Obes (Lond). 2013, 37:140-5. 10.1038/ijo.2012.8
23. Dick KJ, Nelson CP, Tsaprouni L, et al.: DNA methylation and body-mass index: a genome-wide analysis .
Lancet. 2014, 383:1990-8. 10.1016/s0140-6736(13)62674-4
56. Mota MC, De-Souza DA, Rossato LT, et al.: Dietary patterns, metabolic markers and subjective sleep
measures in resident physicians. Chronobiol Int. 2013, 30:1032-41. 10.3109/07420528.2013.796966
57. Sundberg N, Millis RM: A study of diurnal cortisol adaptations in sleep-deprived firefighters during a 72-
hour work shift: a case series. Cureus. 2023, 15:e37504. 10.7759/cureus.37504
58. Gao Y, Davis B, Zhu W, Zheng N, Meng D, Walker WA: Short-chain fatty acid butyrate, a breast milk
metabolite, enhances immature intestinal barrier function genes in response to inflammation in vitro and
in vivo. Am J Physiol Gastrointest Liver Physiol. 2021, 320:G521-30. 10.1152/ajpgi.00279.2020
59. Kahraman S, Dirice E, De Jesus DF, Hu J, Kulkarni RN: Maternal insulin resistance and transient
hyperglycemia impact the metabolic and endocrine phenotypes of offspring. Am J Physiol Endocrinol
Metab. 2014, 307:E906-18. 10.1152/ajpendo.00210.2014
60. Reizel Y, Morgan A, Gao L, et al.: FoxA-dependent demethylation of DNA initiates epigenetic memory of
cellular identity. Dev Cell. 2021, 56:602-612.e4. 10.1016/j.devcel.2021.02.005
61. Nigi L, Grieco GE, Ventriglia G, et al.: microRNAs as regulators of insulin signaling: research updates and
potential therapeutic perspectives in type 2 diabetes. Int J Mol Sci. 2018, 19: 10.3390/ijms19123705
62. Bauer C, Göbel K, Nagaraj N, et al.: Phosphorylation of TET proteins is regulated via O-GlcNAcylation by the
O-linked N-acetylglucosamine transferase (OGT). J Biol Chem. 2015, 290:4801-12. 10.1074/jbc.M114.605881